Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
Uttar Pradesh emerging as leading hub for pharma industry: CM Yogi Adityanath
Chief Minister Yogi Adityanath on Tuesday, February 03, 2026, inaugurated the global congregation of investors and entrepreneurs ‘Uttar Pradesh Pharma Conclave 1.0' in Lucknow. He said that now Uttar Pradesh has become a trusted state for…
/afaqs/media/media_files/2026/02/04/rcb_sunpharma-2026-02-04-13-19-08.jpg)
Sun Pharma onboarded as RCB's principal sponsor for IPL 2026
Sun Pharmaceutical Industries has announced its partnership as the principal sponsor and health partner of Royal Challengers Bengaluru (RCB) for T20 season 2026. This three-year partnership marks Sun Pharma's first-ever foray into cricket…
LSL PHARMA GROUP GRANTS STOCK OPTIONS
BOUCHERVILLE, QC, Feb. 3, 2026 /CNW/ - LSL PHARMA GROUP INC. (TSXV: LSL) (The 'Corporation' or 'LSL Pharma'), a Canadian integrated pharmaceutical company, announced today that it has granted an aggregate of 960,000 stock options ('Options') to its…
Eli Lilly: A Wonderful Company, But A Stock Priced For Perfection (NYSE:LLY)
Eli Lilly is rated SELL due to lofty valuation, despite extraordinary execution and recent market leadership in GLP-1 and obesity drugs. LLY's current $950B market cap implies sustained 25% annual profit compounding for the foreseeable future…
Sun Pharma signs three-year deal as RCB's principal sponsor
Sun Pharmaceutical Industries announced Wednesday it has secured principal sponsorship of Royal Challengers Bengaluru for the T20 season 2026, marking India's largest pharmaceutical company's first cricket partnership. The three-year agreement…
Emcure Pharma Q3 net profit rises 48% YoY at ₹231 cr
Emcure Pharmaceuticals on Wednesday posted a 48 per cent year-on-year increase in its consolidated profit after tax at ₹231 crore for the third quarter ended December 31, 2025, led by robust sales growth in business verticals. The drug firm…
Ex-pharma exec countersues over unique Wu-Tang Clan album
NEW YORK — Martin Shkreli, the convicted former pharmaceutical executive, countersued a digital art collective that paid $4 million for a one-of-a-kind album by the hip-hop group Wu–Tang Clan. In a complaint filed late Monday night in…
WCM Investment Management LLC Sells 14,253 Shares of BridgeBio Pharma, Inc. $BBIO
WCM Investment Management LLC lessened its holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 5.2% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 260,982 shares of the…
BridgeBio Pharma, Inc. $BBIO Shares Acquired by Principal Financial Group Inc.
Principal Financial Group Inc. lifted its position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 23.0% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 1,267,412 shares of the company's…
AE Wealth Management LLC Lowers Holdings in Royalty Pharma PLC $RPRX
AE Wealth Management LLC lowered its position in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 53.7% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 25,121 shares of the…
Royalty Pharma (RPRX) Expected to Announce Quarterly Earnings on Wednesday
Royalty Pharma (NASDAQ:RPRX - Get Free Report) is expected to issue its Q4 2025 results before the market opens on Wednesday, February 11th. Analysts expect the company to announce earnings of $1.28 per share and revenue of $839.9730 million for…
Ascendis Pharma A/S (ASND) Expected to Announce Earnings on Wednesday
Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) is expected to be posting its Q4 2025 results before the market opens on Wednesday, February 11th. Analysts expect the company to announce earnings of $0.13 per share and revenue of $285.3480…
Urogen Pharma (NASDAQ:URGN) Given Average Rating of 'Moderate Buy' by Brokerages
Urogen Pharma (NASDAQ:URGN - Get Free Report) has received an average recommendation of 'Moderate Buy' from the nine ratings firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell…
Watch AI Fears Rattle Markets | Open Interest 2/4/2026
Get a jump start on the US trading day with Matt Miller and Dani Burger on 'Bloomberg Open Interest.' AI fears shake markets—pressuring software, ads, and Wall Street. Pharma splits as Eli Lilly surges and Novo Nordisk warns of a drop.
'Vibrant' Hong Kong market seen drawing more listings from abroad
When Malaysian civil engineering contractor BBSB International listed in Hong Kong last month, its offering was oversubscribed by a factor of nearly 11,000, and its shares rose more than fivefold from their offer price of HK$0.60 on the morning of…
Receive a Daily briefing on Pharma Industry News
Get Started